SecBot SecBot
S-3ASR ·Filed Nov 10, 2026

KURA

Kura Oncology, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 10h ago SEC0001193125-26-455759
Notable filing: S-3ASR
Actionable Insight • Neutral

The ATM facility provides Kura with flexible, opportunistic capital access given its strong cash position and recent commercial momentum. Monitor actual ATM usage in future filings; the company may draw down slowly to fund KOMZIFTI commercialization and ziftomenib/darlifarnib development without urgency, given existing $492M cash and $300M debt facility.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

KURA drug pipeline →

darlifarnib

● Neutral Named in this S-3ASR
Impact
Phase
Phase 1
Time to market
Likely 4-6+ years if successful; still in Phase 1 with registrational Phase 3 planned for 2028 at the earliest
Next catalyst
None dated

What to watchInvestors should watch the KCRS 2026 oral presentation on July 24 and the virtual investor call on July 27 for updated long-term Phase 1a durability data in ccRCC. The program is too early for binary positioning, the real value inflection points (Phase 1b randomization data, Phase 3 start in 2028, and the daraxonrasib combo entering the clinic in early 2027) are 12+ months away. KURA is a multi-asset company with an approved product, so darlifarnib is one of several value drivers.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$7.73
T+0 close · Nov 10, 2026 · via day close
Latest settled
−3.88%
T+1 · $7.43
Vs SPY
−3.53%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $7.73entry
  2. T+1 · 5d ago −3.88%α −3.53% · $7.43
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology filed an automatic shelf registration statement (S-3ASR) as a well-known seasoned issuer, including a base prospectus for an indeterminate amount of common stock, preferred stock, debt securities, and warrants, and a sales agreement prospectus for up to $150 million in at-the-market (ATM) common stock offerings through Leerink Partners and Cantor Fitzgerald. The filing follows strong Q3 2026 results with KOMZIFTI net product revenue of $13.9 million (up 53% sequentially) and a cash position of $492.1 million, plus up to $300 million in additional financing capacity from Oberland Capital. The ATM facility provides flexible capital access to support commercialization and pipeline development, with potential dilution of up to 21.6% of shares outstanding at the current price.

Key Facts

  • S-3ASR filed as a well-known seasoned issuer with no limit on aggregate securities offered
  • Includes a sales agreement prospectus for up to $150 million in ATM common stock sales through Leerink Partners and Cantor Fitzgerald
  • As of September 30, 2026, 91,872,597 shares outstanding; at $7.57/share, $150M represents ~19.8M shares or 21.6% dilution
  • Q3 2026 KOMZIFTI net product revenue of $13.9 million, up 53% sequentially
  • Cash, cash equivalents and short-term investments of $492.1 million as of September 30, 2026
  • Up to $300 million additional financing capacity from Oberland Capital ($275M debt, $25M equity)
  • Proceeds intended for commercialization of KOMZIFTI, pipeline advancement, and general corporate purposes
  • Stock price $7.57 on November 9, 2026; market cap $647 million

Financial Impact

Up to $150 million in potential ATM equity issuance, representing up to 21.6% dilution at current price; company has $492.1M cash plus $300M Oberland facility

dilutioncashshares outstanding

Risk Factors

  • Potential dilution of up to 21.6% if full $150M ATM is utilized at current price
  • ATM sales at prices below current levels would increase dilution
  • Company has no minimum offering amount, so actual usage is uncertain

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
S-3ASR Filing (Primary)0001193125-26-455759
Document: d18057dex48.htm0001193125-26-455759

Track record

29 reports on KURA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Viewing Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 5h 32m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026